Alembic Pharmaceuticals reports higher performance in the April to June quarter, with consolidated net profit increasing by about 12% year-on-year and revenue rising by roughly 26%. In Q1 FY27, the company’s consolidated net profit after tax increases to about ₹175 crore (₹173–₹175 cr reported across outlets), from about ₹156 crore in the same quarter of the previous fiscal year. Revenue from operations grows to around ₹2,150 crore, up from roughly ₹1,710 crore a year earlier. Total consolidated income is reported at approximately ₹2,165 crore, while total consolidated expenses rise to about ₹1,943 crore, compared with lower levels in the year-ago quarter. Consolidated earnings per share increases to around ₹8.80, from about ₹7.85 in Q1 FY26. One report also notes that the board approves the unaudited consolidated and standalone results in a meeting held on 4 August 2026 and that the quarter ended 30 June 2026 was reviewed by an auditor that issued an unmodified conclusion.